Skip to main content

Cardiol Therapeutics (CRDL) Gets a Buy from Canaccord Genuity

Tipranks - Tipranks - Tue Nov 18, 2025

Canaccord Genuity analyst Edward Nash reiterated a Buy rating on Cardiol Therapeutics today and set a price target of $8.00.

Meet Your ETF AI Analyst

Nash covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Celldex, and Inventiva. According to TipRanks, Nash has an average return of 24.7% and a 50.79% success rate on recommended stocks.

In a report released on November 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $9.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of C$2.69 and a one-year low of C$1.09. Currently, Cardiol Therapeutics has an average volume of 142K.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRDL in relation to earlier this year.

Read More on CRDL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).